Key Details
Price
$30.84PE Ratio
13.24Annual ROE
24.68%Beta
0.64Events Calendar
Next earnings date:
Feb 21, 2025Recent quarterly earnings:
Nov 7, 2024Recent annual earnings:
Feb 22, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM ® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interim President and Chief Executive Officer, Founder and Chairman Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Serge Belanger - Needham & Company Oren Livnat - H.C. Wainright Operator Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2024 Earnings Conference Call.
While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.26 per share a year ago.
FAQ
- What is the ticker symbol for Collegium Pharmaceutical?
- Does Collegium Pharmaceutical pay dividends?
- What sector is Collegium Pharmaceutical in?
- What industry is Collegium Pharmaceutical in?
- What country is Collegium Pharmaceutical based in?
- When did Collegium Pharmaceutical go public?
- Is Collegium Pharmaceutical in the S&P 500?
- Is Collegium Pharmaceutical in the NASDAQ 100?
- Is Collegium Pharmaceutical in the Dow Jones?
- When was Collegium Pharmaceutical's last earnings report?
- When does Collegium Pharmaceutical report earnings?
- Should I buy Collegium Pharmaceutical stock now?